Gyre Therapeutics, Inc. (GYRE)
NASDAQ: GYRE · IEX Real-Time Price · USD
+1.75 (12.54%)
At close: Jul 16, 2024, 4:00 PM
+0.05 (0.32%)
After-hours: Jul 16, 2024, 6:27 PM EDT

Company Description

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.

It offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under phase 3 studies for dermatomyositis and systemic sclerosis-associated interstitial lung disease, pneumoconiosis, and diabetic kidney disease.

The company is also involved the development of F351 (Hydronidone), a structural derivative of ETUARY (Pirfenidone), under Phase 3 studies for the treatment of chronic hepatitis B liver fibrosis; and under Phase 1 studies for liver fibrosis associated with nonalcoholic associated steatohepatitis.

In addition, its development pipeline includes F573, under Phase 2 studies for the treatment of acute/acute-on-chronic liver failure; F528, under preclinical stage for the treatment of chronic obstructive pulmonary disease; and F230, under preclinical stage for the treatment of pulmonary arterial hypertension.

The company was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Gyre Therapeutics, Inc.
Gyre Therapeutics logo
Country United States
Founded 2002
Industry Biotechnology
Sector Healthcare
Employees 593
CEO Dr. Han Ying Ph.D.

Contact Details

12770 High Bluff Drive, Suite 150
San Diego, California 92130
United States
Phone (619) 949-3681

Stock Details

Ticker Symbol GYRE
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001124105
ISIN Number US4037831033
Employer ID 56-2020050
SIC Code 2834

Key Executives

Name Position
Dr. Han Ying Ph.D. Chief Executive Officer and Director
Songjiang Ma President and Director
Ruoyu Chen Interim Chief Financial Officer
Weiguo Ye Chief Operating Officer
Seline E. Miller CPA Senior Vice President of Finance

Latest SEC Filings

Date Type Title
Jul 16, 2024 144 Filing
Jul 15, 2024 144 Filing
Jul 12, 2024 RW Filing
Jul 12, 2024 RW Filing
Jul 5, 2024 8-K Current Report
Jul 3, 2024 144 Filing
Jul 2, 2024 144 Filing
Jul 1, 2024 144 Filing
Jun 28, 2024 144 Filing
Jun 17, 2024 8-K Current Report